- Active not recruitingPHASE1, PHASE2
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
This study is looking at new ways to treat advanced prostate cancer that has spread and medicines like hormone therapy no longer work. Researchers are testing the drug pembrolizumab, sometimes with other treatments, to see if it's safe and effective, aiming to find better options for patients.
For: Metastatic Castration-Resistant Prostate CancerUnited States · Denmark · France - Active not recruitingPHASE2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
This study is looking at new ways to treat advanced liver and bile duct cancers. It tests new medicines, called immunomodulators, either on their own or alongside other cancer drugs, to see how well they work and if they are safe.
For: Hepatocellular Carcinoma · Biliary Tract CancerUnited States · China · Hong Kong - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
For: Solid Tumors · Hematologic MalignanciesUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
This study compares two treatments for advanced kidney cancer: a combination of belzutifan and lenvatinib, versus cabozantinib. It's for people whose cancer has grown even after previous treatment, aiming to find which option works better and is safer.
For: Carcinoma, Renal CellUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
This study looks at new drug combinations for advanced kidney cancer that has not responded to previous treatments. It aims to see how safe and effective these new combinations are.
For: Carcinoma, Renal CellUnited States · Australia · Canada - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
This study tested new drug combinations for advanced oesophageal cancer. It looked at pembrolizumab with lenvatinib and chemotherapy, versus pembrolizumab and chemotherapy, to see which worked best and was safest. The study has now stopped, with no safety concerns being the reason.
For: Metastatic Esophageal Squamous Cell CarcinomaUnited States · Argentina · Canada - RecruitingPHASE3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
This study looks at the long-term effects of a medicine called belzutifan for people with advanced cancers or cancers linked to Von Hippel-Lindau disease. It's for those already taking belzutifan in other trials. The aim is to see how long people live after starting this treatment.
For: Von Hippel-Lindau Disease · Carcinoma, Renal CellUnited States · Belgium · Canada - Active not recruitingPHASE1, PHASE2
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
This study is looking at new combinations of medicines for kidney cancer (renal cell carcinoma) that has spread or come back. We want to see how safe and effective these new treatments are. It's an early-stage study to find the best way to use these combinations.
For: Carcinoma, Renal CellUnited States · Australia · Canada - RecruitingPHASE2
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
This study looks at new treatments for advanced liver cancer that hasn't responded to initial therapy. It combines a new medicine, visugromab, with existing treatments (nivolumab and lenvatinib) to see if this mix is more effective and safe than lenvatinib alone.
For: Unresectable or Metastatic Hepatocellular Carcinoma · Child-Pugh A Hepatocellular Carcinoma · Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 CompoundGermany · Italy - Active not recruitingPHASE3
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
This study for advanced kidney cancer compares a standard treatment, Sunitinib, with two new combinations: Lenvatinib plus Everolimus, or Lenvatinib plus Pembrolizumab. The aim is to see if either new combination can keep the cancer from growing for longer. It's in the final stage of testing.
For: Renal Cell CarcinomaUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
This study is testing a new drug, Farletuzumab Ecteribulin, for certain advanced cancers like ovarian, endometrial, and some breast and lung cancers. Researchers want to see if it's safe, how well it works, and find the best dose.
For: Solid TumorUnited States · France · Japan - Active not recruitingPHASE3
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This study looks at new drug combinations for advanced liver cancer that has already been treated. It compares atezolizumab with lenvatinib or sorafenib against lenvatinib or sorafenib alone, to see if the combinations work better and are safe.
For: Unresectable Hepatocellular CarcinomaAustria · Belgium · Brazil - Active not recruitingPHASE1
Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors
This study is looking at two new drugs, Avelumab and Lenvatinib, combined together to treat children and teenagers with specific types of brain tumours. It aims to find the right dose and see how well this combination works.
For: Central Nervous System TumorsCanada · France · Germany - Active not recruitingPHASE1
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
This study looks at new drug combinations for advanced kidney cancer. We want to see how safe and effective MEDI5752 is when given with either Lenvatinib or Axitinib to people with this type of cancer.
For: Advanced Renal Cell CarcinomaUnited States · Australia · France - Active not recruitingPHASE2
Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
This study is testing if a combination of two drugs, pembrolizumab and lenvatinib, works better than pembrolizumab alone for people with a type of head and neck cancer. This is given after initial treatment.
For: Head and Neck Squamous Cell CarcinomaGermany - Active not recruitingPHASE1, PHASE2
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
This study is testing a new drug, E7386, alongside other cancer medicines. It aims to find the safest and most effective dose for people with various solid tumours, especially endometrial cancer, and to understand how these combinations work.
For: Endometrial Neoplasms · Neoplasms · Carcinoma, HepatocellularUnited States · Canada · China - RecruitingPHASE2
Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
This study looks at new ways to treat liver cancer before and after surgery. We're testing two drugs, pembrolizumab and lenvatinib, alone or together, to see if they can help stop the cancer from coming back after removal. It’s for people with liver cancer that can be surgically removed.
For: Hepatocellular CarcinomaUnited Kingdom - Active not recruitingPHASE3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
This study is testing new combinations of medicines for advanced kidney cancer (renal cell carcinoma). Its aim is to see if these new combinations work better and are safe compared to a standard treatment, for people who haven't had treatment for their advanced cancer before.
For: Carcinoma, Renal CellUnited States · Australia · Brazil - Active not recruitingPHASE3
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
This study is testing two new drugs, nivolumab and ipilimumab, together for advanced liver cancer (hepatocellular carcinoma). It compares this combination to standard treatments (sorafenib or lenvatinib) to see if it helps people live longer. Participants haven't had prior treatment.
For: Hepatocellular CarcinomaUnited States · Argentina · Australia